Diagnosing & Treating Vitiligo in 2022 and What’s To Come
169381693816938
As a former vitiligo clinical trials research fellow, I have attended more than my fair share of presentations on vitiligo. Yet, I am amazed at how each additional lecture continues to teach me new and exciting concepts and treatment options for vitiligo. Dr. Seemal Desai’s lecture at the 2022 Skin of Color Update Conference was no exception to this rule.
During the SOCU Conference held in Ne …
As a former vitiligo clinical trials research fellow, I have attended more than my fair share of presentations on vitiligo. Yet, I am amazed at how each additional lecture continues to teach me new and exciting concepts and treatment options for vitiligo. Dr. Seemal Desai’s lecture at the 2022 Skin of Color Update Conference was no exception to this rule.
During the SOCU Conference held in Ne … Continue reading "Diagnosing & Treating Vitiligo in 2022 and What’s To Come"
Upadacitinib (RINVOQ®) is a once daily oral medication that is FDA approved for a variety of conditions including psoriatic arthritis and atopic dermatitis. Jak inhibitors, like upadacitinib, are a class of drugs showing to be effective in treating inflammatory conditions. Upadacitnib is not only being used to treat rheumatoid arthritis and psoriatic arthritis, but was recently FDA approved i … 
Next Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources, interviewed Dr. David E. Cohen (Charles C. and Dorothea E. Harris Professor of Dermatology, Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine) on patch testing for allergic contact dermatitis in atopic dermatitis pati … 
Allure recently posted a first-person account of acne excoriée. How can dermatologists best counsel patients who pick their acne lesions, and what tools can help address the urge to pick?
For expert advice, I reached out to dermatologist and clinical psychologist Rick Fried, MD, PhD, clinical director of Yardley Dermatology Associates and Yardley Clinical Research Associates in Yardley, Pa.
… 
Chronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr … 